CV Benefits of Lipoprotein(a) Reduction With PCSK9 Inhibitors
Investigators evaluated whether lower on-study and greater percentage reductions in lipoprotein(a) are associated with a lower risk for major adverse cardiovascular events.
All articles by Amit Akirov, MD
Hypertension Linked to Glucocorticoid Sensitivity in Women Without Hypercortisolism
Hypertension may be associated with degree of glucocorticoid suppression and peripheral activation in postmenopausal women.
Unrecognized MI Is Common, Increases Mortality Risk in Asymptomatic Patients With Diabetes
Researchers conducted a prospective study focusing on asymptomatic patients with diabetes to investigate the prevalence and prognostic significance of unrecognized MI.
Intensive Blood Pressure Therapy May Reduce Vascular Morbidity in T2D
Intense antihypertensive treatment with perindopril-indapamide may reduce all-cause mortality and major vascular events in type 2 diabetes, irrespective of baseline blood pressure or 10-year risk for atherosclerotic cardiovascular disease.
Effects of Linagliptin on Cardiovascular Outcomes in T2D and Kidney Disease
Treatment with linagliptin in patients with type 2 diabetes and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events.
Cardiovascular Effects of Canagliflozin Vary According to Concomitant Metformin Use
The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin.
Glucose Screening in Pregnancy Identifies Future CVD Risk in Women
Glucose screening during pregnancy can predict future cardiovascular (CV) risk in women with and without gestational diabetes, according to study results published in The Lancet Diabetes & Endocrinology. CV risk was found to be higher with abnormal glucose screening tests, but there was also increased CV risk in women with glucose concentrations at the upper…
Evolocumab Plus Statin Effectively Reduces LDL-C in T2D With Hyperlipidemia
Investigators examined the safety and lipid‐lowering efficacy of evolocumab combined with atorvastatin in patients with type 2 diabetes and hyperlipidemia or mixed dyslipidemia.
Does Parathyroidectomy Reduce CV Risk in Primary Hyperparathyroidism?
Parathyroidectomy may have a potential beneficial effect on lipid profiles and decrease cardiovascular risk in patients with primary hyperparathyroidism.
Bempedoic Acid Improves Lipid Control When Added to Statin Therapy
Bempedoic acid, an investigational ATP citrate lyase inhibitor, might safely lower low-density lipoprotein cholesterol levels when added to statin therapy.
Next post in Dyslipidemia
